AUGUST 10, 2026 INVESTOR DEADLINE: Erasca, Inc. (ERAS) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Erasca, Inc. (NASDAQ: ERAS) common stock between January 14, 2025 and April 26, 2026, both dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the Erasca class action lawsuit.

Captioned Cheng v. Erasca, Inc. , No. 26-cv-03481 (S.D. Cal.), the Erasca class action lawsuit charges Erasca as well as certain of Erasca's executive officers with violations of the Securities Exchange Act of 1934.

Erasca is a clinical-stage precision oncology company that focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors.

The Erasca class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) ERAS-0015's preclinical data was based on improper comparisons to Revolution Medicines, Inc. and placed Erasca at risk of violating patent and trade secret protections; and (ii) based on the foregoing, the defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

On April 27, 2026, before the market opened, Erasca allegedly disclosed that it received a letter from Revolution Medicines, Inc. asserting that Erasca's ERAS-0015 infringes on a Revolution Medicines, Inc. patent and is connected to alleged trade secret misappropriation. On this news, the price of Erasca stock fell nearly 11%, according to the complaint.

The Erasca class action lawsuit further alleges that after market close on April 27, 2026, Erasca reported preliminary Phase I clinical data for ERAS-0015 and disclosed that one patient who received 24 mg of ERAS-0015 had died approximately one month after starting ERAS-0015. Erasca allegedly further disclosed that comparisons between ERAS-0015 and other product candidates were based on cross-study analyses and "not based on any head-to-head clinical trials," and that such comparisons are "inherently limited and such data may not be directly comparable."

On this news, the price of Erasca stock declined more than 48%, according to the complaint.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Erasca common stock during the Class Period to seek appointment as lead plaintiff in the Erasca class action lawsuit.

A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Erasca class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Erasca class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Erasca class action lawsuit.